Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202188 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,144
- Enrollment target
NCT01202188 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,144 participants.
The verdict
NCT01202188, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,144 participants
- Enrollment target
Study Summary
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
Interventions
- DRUG placebo
- DRUG tiotropium
- DRUG indacaterol and glycopyrronium (QVA149)
- DRUG glycopyrronium (NVA237)
- DRUG indacaterol (QAB149)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,144 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202188
The ClinicalTrials.gov registry entry for NCT01202188 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01202188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202188 about?
NCT01202188 is a clinical study titled "A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.
What is the current status of trial NCT01202188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,144 participants. The study started on 2010-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01202188?
The interventions under investigation include: placebo (DRUG), tiotropium (DRUG), indacaterol and glycopyrronium (QVA149) (DRUG), glycopyrronium (NVA237) (DRUG), indacaterol (QAB149) (DRUG).
Who is sponsoring clinical trial NCT01202188?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.